NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)

News

NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering [Yahoo! Finance]
NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at Wall Str
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com